Observational study of progressive pulmonary fibrosis (PPF) in China
Part of Lungs & breathing clinical trials.
This study is a registry that collects information from people in China who have progressive pulmonary fibrosis (PPF), a lung condition that gets worse over time. It aims to better understand the disease and help doctors improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with progressive pulmonary fibrosis (PPF) in the last year.
- You must not have idiopathic pulmonary fibrosis (IPF).
- You must have had a high-resolution CT (HRCT) scan of your chest.
- You must be willing to sign a consent form to join the study.
- You cannot be taking part in another medication trial right now (unless that trial is over or you've been off the study drug for at least 2 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds a community registry to learn about people affected by pulmonary fibrosis and related lung conditions, including patients, caregivers, and close family. By joining, you help researchers better understand needs and experiences in the real world.
This study tests an experimental medicine called HSK44459 to see if it can slow down progressive pulmonary fibrosis (PPF), a condition that causes lung scarring and breathing difficulty. The goal is to learn if the medicine can help people keep more of their lung function compared to a placebo.
This study looks at how well people with pulmonary fibrosis can breathe in and aims to see if their breathing flow rate is linked to their condition. It may help doctors understand more about the disease and plan better care.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
This study looks at how patients and doctors decide on treatment for pulmonary fibrosis. It aims to understand the impact of side effects from antifibrotic medicines on treatment choices.
Hear when a new Progressive Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.